Latest News for: oncolytic

Edit

Oncolytic Virus Cancer Therapy Pipeline Shows Strong Momentum as 120+ Pharma Companies in the Race ...

GetNews 17 Jun 2026
Explore our latest breakthroughs in Oncolytic Virus Cancer Therapy Research @ ... Oncolytics Biotech ... Oncolytic viruses exert their oncolytic effects by directly lysing tumor cells or stimulating the host to produce an anti-tumor immune response.
Edit

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044 (Form 8-K) (Oncolytics Biotech Inc)

Public Technologies 16 Jun 2026
) Oncolytics Biotech® Secures New U.S ... SAN DIEGO, CA, June 16, 2026 - Oncolytics Biotech® Inc ... About Oncolytics Biotech Inc ... Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact.
Edit

Oncolytics Biotech� Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

Nasdaq Globe Newswire 16 Jun 2026
Oncolytics Biotech announced that the USPTO has issued a new patent broadly protecting the proprietary manufacturing process for pelareorep into 2044 ... .
Edit

Recipharm and Fusix Biotech advance novel oncolytic virus platform (Recipharm AB)

Public Technologies 08 Jun 2026
Fusix Biotech is developing breakthrough cancer treatments using proprietary oncolytic fusion virus technology designed to combine direct tumour cell destruction with modulation of the tumour microenvironment to enhance anti-tumour immune responses.
Edit

Initial Statement of Beneficial Ownership (Form 3) (Oncolytics Biotech Inc)

Public Technologies 03 Jun 2026
) FORM 3. UNITED STATES SECURITIES AND EXCHANGE COMMISSION. Washington, D.C ... OMB Number. 3235-0104 ... 0.5 ... 2 ... ONCOLYTICS BIOTECH INC [ONCY] ... C/O ONCOLYTICS BIOTECH INC., 4350 EXECUTIVE DRIVE, SUITE 325 4 ... 5 ... 5) ... C/O ONCOLYTICS BIOTECH INC ... Oncolytics Biotech Inc.
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Oncolytics Biotech Inc)

Public Technologies 03 Jun 2026
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue ... 0.5 ... ONCOLYTICS BIOTECH INC [ONCY] 5 ... C/O ONCOLYTICS BIOTECH INC., 4350 EXECUTIVE DRIVE, SUITE 325 3 ... C/O ONCOLYTICS BIOTECH INC ... Oncolytics Biotech Inc.
Edit

Oncolytics Biotech� Announces Appointment of Steve Glover to Board of Directors and Promotion of John ...

Nasdaq Globe Newswire 02 Jun 2026
Oncolytics Biotech announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer ... .
Edit

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer (Form 8-K) (Oncolytics Biotech Inc)

Public Technologies 02 Jun 2026
) Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer. SAN DIEGO, CA, June 2, 2026 - Oncolytics Biotech® Inc ... About Oncolytics Biotech Inc ... jpatton@oncolytics.com.
Edit

Oncolytics Biotech� Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with ...

Nasdaq Globe Newswire 01 Jun 2026
Oncolytics announced data demonstrating evidence of greater anti-tumor activity with pelareorep in combination with RAS inhibitor modalities ... .
Edit

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches (Form 8-K) (Oncolytics Biotech Inc)

Public Technologies 01 Jun 2026
) Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches ... SAN DIEGO, CA, June 1, 2026 - Oncolytics Biotech® Inc ... About Oncolytics Biotech Inc.
Edit

China-US Dual Filing Success: Porton Advanced's End-to-End Bacterial Vector CDMO Solution Accelerates NMPA Approval of Salvectors' Innovative Oncolytic Bacteria Therapy

PR Newswire 28 May 2026
SUZHOU, China and CRANBURY, N.J., May 28, 2026 /PRNewswire/ -- Porton Advanced, a leading cell and gene therapy CDMO, recently announced its client Salvectors has received Investigational New Drug ...
Edit

From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger ...

Black Hills Pioneer 27 May 2026
SAN DIEGO, CA / ACCESS Newswire / May 26, 2026 / Biotech investors spend enormous amounts of time searching for "the next big thing." Most never stop to ask a more important question ....
Edit

Enhancing Oncolytic Virus Efficacy with Creative Biolabs’ One-Stop Vaccinia Virus Enhancement Service

Killeen Daily Herald 26 May 2026
Just another WordPress site ....
Edit

Enhancing Oncolytic Virus Efficacy with Creative Biolabs’ One-Stop Vaccinia Virus Enhancement Service

GetNews 26 May 2026
New York, USA - May 25, 2026 - Creative Biolabs is at the forefront of advancing oncolytic virus therapy development, particularly specializing in oncolytic vaccinia virus enhancement by improving virus replication, tumor selectivity, and efficacy.
Edit

From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story

Pharmiweb 26 May 2026
That is part of what makes Oncolytics Biotech increasingly interesting to investors following the immunotherapy space ... Explain the significance of that concept and, particularly, why it may be so important to the broader Oncolytics strategy.

Article Search

tools
×
×
×
×